Canadian biotech and animal health firm Prevtec Microbia has raised $4.7 million in a round led by animal health-focused venture capital firm Vet Venture Capital. The firm committed $3 million, according to a press release.
Existing shareholders start-up investor Telesystem, asset management firm Groupe Jafaco Gestion and venture capital firm Desjardins-Innovatech also contributed to the round.
“Our mission is to bring multiple innovative products to market in the coming years and collaborate efficiently with our key partners,” said Michel Fortin, president and chief executive of Prevtec Microbia in a statement.
The company is planning to launch a live bacterial swine vaccine, designed to combat a strain of E. coli, commercially this year across some European Union countries. And it has secured a distribution agreement with Elanco, an animal health specialist in the EU.